Patritumab Deruxtecan (Fixed dose) clinical trials

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

This study looks at a new treatment called patritumab deruxtecan for people with an advanced type of lung cancer that has a specific genetic change (EGFR mutation). It's for those who have already tried other standard treatments that are no longer working.